Uncomplicated Urinary Tract Infections: Pathogens, Resistance & Treatment Options

Uncomplicated urinary tract infections (UTIs) extend beyond physical discomfort, imposing emotional and social strains, particularly when episodes recur.

Many adults experience at least one UTI in their lifetime, with recurrence common in susceptible individuals. Even when confined to the lower urinary tract, repeated episodes reduce quality of life, increase healthcare visits, and cause anxiety.

Clinical management is challenging due to patient variability and the lack of a single classification standard.

Current guidelines classify UTIs as localised or systemic, with uncomplicated cases confined to the bladder in afebrile adults, causing dysuria, frequency, urgency, or suprapubic pain.

Treatment should consider patient-specific factors, including resistance risk, allergies, contraindications, and drug interactions.

UTIs arise from ascending rectal flora, disrupted vaginal microbiota, or persistent bladder pathogens.

Escherichia coli predominates, while recurrence in women often links to sexual activity or contraception, and in men may signal anatomical or functional issues.

Rising resistance to first-line oral antimicrobials poses a significant challenge, especially where rapid diagnostics are unavailable.

Reports of drug-resistant strains, including ESBL and carbapenemase-producing E coli, are rising, often showing co-resistance that limits oral treatment options.

Recent approvals of newer oral agents for uncomplicated UTIs provide additional options, enabling clinicians to balance efficacy, tolerability, treatment duration, and the avoidance of intravenous therapy or hospitalisation whenever possible.

Clinicians manage uncomplicated UTIs most effectively by adopting a comprehensive, patient-centred approach that accounts for recurrence risk, local resistance patterns, and individual treatment preferences.

With evolving classifications and emerging oral therapies, healthcare providers can reduce the burden of these common infections while preserving long-term antimicrobial effectiveness.